HC Wainwright Initiates Coverage on Pasithea Therapeutics With Buy Rating, $3 Price Target
AI Sentiment
Positive
6/10
as of 12-12-2025 4:00pm EST
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | MIAMI BEACH |
| Market Cap: | 5.3M | IPO Year: | 2021 |
| Target Price: | $3.00 | AVG Volume (30 days): | 21.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.28 - $3.85 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
KTTA Breaking Stock News: Dive into KTTA Ticker-Specific Updates for Smart Investing
AI Sentiment
Positive
6/10
See how KTTA stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "KTTA Pasithea Therapeutics Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.